The human POMC gene promoter: Where do we stand?

Journal of Endocrinological Investigation

Volumn 34, Issue 6, 2011, Pages 454-460

  Giraldi, F Pecori ^a,b   Cassarino, F ^a   Pagliardini, L ^b   Asnaghi, V ^a   Cavagnini, F ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

ACTH; ACTH secreting tumor (cushing's disease or syndrome); Corticosteroids; CRH; Cytokine; Leukemia inhibitory factor (LIF); Pituitary; Proopiomelanocortin (POMC); TPIT; Transcription factors

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GLUCOCORTICOID; PROOPIOMELANOCORTIN; TRANSCRIPTION FACTOR;

GENE CONTROL; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE STRUCTURE; HORMONE RESPONSIVE ELEMENT; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; SHORT SURVEY; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION;

GENE EXPRESSION REGULATION; HUMANS; PRO-OPIOMELANOCORTIN; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 79960920090     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7613     Document Type: Short Survey

References (75)

1. Takahashi H, Teranishi Y, Nakanishi S, Numa S. Isolation and structural organization of the human corticotropin-β-lipotropin precursor gene. FEBS Lett 1981, 135: 97-102.
2. Clark AJL, Lavender PM, Coates P, Johnson MR, Rees LH. In vitro and in vivo analysis of the processing and fate of the peptide products of the short proopiomelanocortin mRNA. Mol Endocrinol 1990, 4: 1737-43.
3. Lacaze-Masmonteil T, De Keyzer Y, Luton JP, Kahn A, Bertagna X. Characterization of proopiomelanocortin transcripts in human non-pituitary tissues. Proc Natl Acad Sci U S A 1987, 84: 7261-5.
4. Notake M, Kurosaki T, Yamamoto T, Handa H, Mishina M, Numa S. Sequence requirement for transcription in vitro of the human corticotropin/β- lipotropin precursor gene. Eur J Biochem 1983, 133: 599-605.
5. Riegel AT, Remenick J, Wolford RG, Berard DS, Hager GL. A novel transcriptional activator (PO-B) binds between the TATA box and cap site of the proopiomelanocortin gene. Nucleic Acids Res 1990, 18: 4513-21.
6. Liu B, Mortrud M, Low MJ. DNA elements with AT-rich core sequences direct pituitary cell-specific expression of the pro-opiomelanocortin gene in transgenic mice. Biochem J 1995, 312: 827-32.
7. Bumaschny V, de Souza FSJ, López Leal RA, et al. Transcriptional regulation of pituitary POMC is conserved at the vertebrate extremes despite great promoter sequence divergence. Mol Endocrinol 2007, 21: 2738-49.
8. Therrien M, Drouin J. Pituitary pro-opiomelanocortin expression requires synergistic interactions of several regulatory elements. MoI Cell Biol 1991, 11: 3492-503. (Pubitemid 21895736)
9. Picon A, Bertagna X, De Keyzer Y. Analysis of proopiomelanocortin gene transcription mechanisms in bronchial tumour cells. Mol Cell Endocrinol 1999, 147: 93-102. (Pubitemid 29090397)
10. Murakami I, Takeuchi S, Kudo T, Sutou S, Takahashi S. Corticotropin-releasing hormone or dexamethasone regulates rat proopiomelanocortin transcription through Tpit/Pitx-responsive element in its promoter. J Endocrinol 2007, 193: 279-90.
11. Poulin G, Turgeon B, Drouin J. NeuroD1/β2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol 1997, 17: 6673-82.
12. Philips A, Lesage S, Gingras R, et al. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 1997, 17: 5946-51.
13. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006, 20: 2871-86. (Pubitemid 44771748)
14. Nudi M, Ouimette JF, Drouin J. Bone morphogenic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity. MoI Endocrinol 2005, 19: 1329-42.
15. Therrien M, Drouin J. Cell-specific helix-loop-helix factor required for pituitary expression of the pro-opiomelanocortin gene. Mol Cell Biol 1993, 13: 2342-53. (Pubitemid 23097713)
16. Lamonerie T, Tremblay J, Lanctôt C, Therrien M, Gauthier Y, Drouin J. PTX1, a bicoid-related homeobox transcription factor involved in transcription of pro-opiomelanocortin (POMC) gene. Genes Dev 1996, 10: 1284-95. (Pubitemid 26171108)
17. Maira M, Couture C, Le Martelot G, Pulichino AM, Bilodeau S, Drouin J. The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action. J Biol Chem 2003, 278: 46523-32. (Pubitemid 37452225)
18. Abbud RA, Kelleher R, Melmed S. Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expression. Endocrinology 2004, 145: 867-80.
19. Drouin J, Maira M, Philips A. Novel mechanism of action for Nur77 and antagonism by glucocorticoids: a convergent mechanism for CRH activation and glucocorticoid repression of POMC gene transcription. J Steroid Biochem MoI Biol 1998, 65: 59-63.
20. Bucciarelli LG, Pecori Giraldi F, Cavagnini F. No mutations in TPIT, a corticotroph-specific gene, in human tumoral pituitary ACTH-se creting cells. J Endocrinol Invest 2005, 28: 1015-8. (Pubitemid 43265768)
21. Giacomini D, Páez Pereda M, Theodoropoulou M, et al. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 2006, 147: 247-56.
22. Ikeda M, Kakuyama M, Shoda T, Iwasaki Y, Fukuda K. Potentiation of cyclic AMP-mediated proopiomelanocortin gene promoter activity by calcium channel blockers in a pituitary cell line. Eur J Pharmacol 2007, 558: 1-6.
23. Kovalovsky D, Refojo D, Liberman AC, et al. Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 2002, 16: 1638-51.
24. Boutillier AL, Gaiddon C, Lorang D, Roberts JL, Loeffler JP. Transcriptional activation of the proopiomelanocortin gene by cyclic AMP-responsive element binding protein. Pituitary 1998, 1: 33-43.
25. Autelitano DJ. Glucocorticoid regulation of c-fos, c-jun and transcription factor AP-1 in the AtT-20 corticotrope cell. J Neuroendocrinol 1994, 6: 627-37.
26. Boutillier AL, Monnier D, Lorang D, Lundblad JR, Roberts JL, Loeffler JP. Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. Mol Endocrinol 1995, 9: 745-55.
27. Kraus J, Höllt V. Identification of a cAMP-response element on the human proopiomelanocortin gene upstream promoter. DNA Cell Biol 1995, 14: 103-10.
28. Fukuda K, Uetsuki N, Uga H, et al. Potentiation of proopiomeanocortin gene expression in culture pituitary cells by benzodiazepines. Anesthesiology 2003, 98: 1172-7.
29. Ikeda M, Kakuyama M, Shoda T, Fukuda K. Enhancement of proopiomelanocortin gene promoter activity by local anesthetics in a pituitary cell line. Reg Anesth Pain Med 2007, 32: 60-6.
30. Morishita M, Iwasaki Y, Yamamori E, et al. Antidiabetic sulfonylurea enhances secretagogue-induced adrenocorticotropin secretion and proopiomelanocortin gene expression in vitro. Endocrinology 2000, 141: 3313-8. (Pubitemid 32269020)
31. Zhao LF, Iwasaki Y, Oki Y, et al. Purinergic receptor ligands stimulate pro-opiomelanocortin gene expression in AtT-20 pituitary corticotroph cells. J Neuroendocrinol 2006, 18: 273-8.
32. Jin WD, Boutillier AL, Glucksman MJ, Salton SRJ, Loeffler JP, Roberts JL Characterization of a corticotropin-releasing hormone-responsive element in the rat proopiomelanocortin gene promoter and molecular cloning of its binding protein. Mol Endocrinol 1994, 8: 1377-88.
33. Murphy EP, Conneely OM. Neuroendocrine regulation of the hypothalamic-pituitary-adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. Mol Endocrinol 1997, 11: 39-47.
34. Maira M, Martens C, Philips A, Drouin J. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 1999, 19: 7549-57.
35. Batsché E, Desroches J, Bilodeau S, Gauthier Y, Drouin J. Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness. J Biol Chem 2005, 280: 19746-56.
36. Vila G, Papazoglou M, Stalla J, et al. Sonic hedgehog regulates CRH signal transduction in the adult pituitary. FASEB J 2005, 19: 281-3. (Pubitemid 40189282)
37. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C. NF-κB participates in the corticotropin-releasing hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem 2004, 279: 10837-40.
38. Labeur M, Refojo D, Wölfel B, et al. Interferon-γ inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. J Endocrinol 2008, 199: 177-89.
39. Taguchi T, Takao T, Iwasaki Y, Nishiyama M, Asaba K, Hashimoto K. Suppressive effects of dehydroepiandrosterone and the nuclear factor-kB inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo. J Endocrinol 2006, 188: 321-31.
40. Takayasu S, Iwasaki Y, Nigawara T, et al. Involvement of nuclear factor-KB and Nurr-1 in cytokine-induced transcription of proopiomelanocortin gene in AtT20 corticotroph cells. Neuroimmunomodulation 2010, 17: 88-96.
41. Asaba K, Iwasaki Y, Asai M, et al. High glucose activates pituitary proopiomelanocortin gene expression: possible role of free radical-sensitive transcription factors. Diabetes Metab Res Rev 2007, 23: 317-23.
42. Tsukamoto N, Otsuka F, Miyoshi T, et al. Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pitutary corticotrope cells: involvement of up-regulation of BMP receptor signaling by somatostatin analogs. Endocrinology 2010, 151: 1129-41.
43. Turney MK, Kovacs WJ. Function of a truncated glucocorticoid receptor form at a negative glucocorticoid response element in the proopiomelanocortin gene. J MoI Endocrinol 2001, 26: 43-9.
44. Drouin J, Sun YL, Chamberland M, et al. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J 1993, 12: 145-58.
45. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998, 93: 531-41. (Pubitemid 28240715)
46. Mönig H, Ali IU, Oldfield EH, Schulte HM. Structure of the POMC promoter region in pituitary and extrapituitary ACTH-producing tumors. Exp Clin Endocrinol 1993, 101: 36-8. (Pubitemid 23097244)
47. Chang ACY, Israel A, Gazdar A, Cohen SN. Initiation of pro-opiomelanocortin mRNA from a normally quiescent promoter in a human small cell lung carcinoma. Gene 1989, 84: 115-26.
48. Philips A, Maira M, Mullick A, et al. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol 1997, 17: 5952-9. (Pubitemid 27411102)
49. Okabe T, Takayanagi R, Adachi M, Imasaki K, Nawata H. Nur77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotrope cells. J Endocrinol 1998, 156: 169-75.
50. Invitti C, Pecori Giraldi F, De Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multi-centre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999, 84: 440-8.
51. Jiang J, Li N, Wang X, et al. Aberrant expression and modification of silencing mediator of retinoic acid and thyroid hormone receptors involved in the pathogenesis of tumoral cortisol resistance. Endocrinology 2010, 151: 3697-705.
52. Latchoumanin O, Mynard V, Devin-Leclerc J, Dugué MA, Bertagna X, Catelli MG. Reversal of glucocorticoid-dependent proopiomelanocortin gene inhibition by leukemia inhibitory factor. Endocrinology 2007, 148: 422-32.
53. Páez Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing's syndrome. J Clin Invest 2001, 108: 1123-31.
54. Matsumoto S, Hashimoto K, Yamada M, Satoh T, Hirato J, Mori M. Liver X receptor-α regulates proopiomelanocortin (POMC) gene transcription in the pituitary. Mol Endocrinol 2009, 23: 47-60.
55. Mynard V, Guignat L, Devin-Leclerc J, Bertagna X, Catelli MG. Different mechanisms for leukemia inhibitory factor-dependent activation of two proopiomelanocortin promoter regions. Endocrinology 2002, 143: 3916-24.
56. Auernhammer CJ, Kopp FB, Vlotides G, et al. Comparative study of gp130 cytokine effects on corticotroph AtT-20 cells - Redundancy or specificity of neuroimmunoendocrine modulators? Neuroimmunomodulation 2004, 11: 224-32.
57. Yano H, Readhead C, Nakashima M, Ren SG, Melmed S. Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. MoI Endocrinol 1998, 12: 1708-20.
58. Chesnokova V, Auernhammer CJ, Melmed S. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 1998, 139: 2209-16.
59. Iwasaki Y, Taguchi T, Nishiyama M, et al. Lipopolysaccharide stimulates proopiomelanocortin gene expression in AtT20 corticotroph cells. Endocr J 2008, 55: 285-90.
60. Kumagai C, Takao T, Matsumoto R, Asaba K, Hashimoto K. Modulation of interleukin-1 receptors followed by endotoxin lipopolysaccharide treatment in the mouse AtT-20 pituitary tumor cell line. Neuroimmunomodulation 2003, 10: 310-6. (Pubitemid 36649367)
61. Mynard V, Latchoumanin O, Guignat L, et al. Synergistic signaling by corticotropin-releasing hormone and leukemia inhibitory factor bridged by phosphorilated 3′,5′-cyclic adenosine monophosphate response element binding protein at the Nur response element (NurRE)-signal transducers and activators of transcription (STAT) element of the proopiomelanocortin promoter. Mol Endocrinol 2004, 18: 2997-3010.
62. Kovalovsky D, Péez Pereda M, Labeur MS, et al. Nur77 induction and activation are necessary for interleukin-1 stimulation of proopiomelanocortin in AtT-20 corticotrophs. FEBS Lett 2004, 563: 229-33.
63. Bousquet C, Zatelli MC, Melmed S. Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno- neuroendocrine interfacing. J Clin Invest 2000, 106: 1417-25.
64. Bousquet C, Ray DW, Melmed S. A common pro-opiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy. J Biol Chem 1997, 272: 10551-7.
65. Akita S, Webster J, Ren SG, et al. Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. J Clin Invest 1995, 95: 1288-98.
66. Bousquet C, Susini C, Melmed S. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest 1999, 104: 1277-85. (Pubitemid 29536298)
67. Katahira M, Iwasaki Y, Aoki Y, Oiso Y, Saito H. Cytokine regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. Endocrinology 1998, 139: 2414-22. (Pubitemid 28513767)
68. Gardiner-Garden M, Frommer M. Transcripts and CpG islands associated with the pro-opiomelanocortin gene and other neurally expressed genes. J Mol Endocrinol 1994, 12: 365-82.
69. Newell-Price J, King P, Clark AJL. The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Mol Endocrinol 2001, 15: 338-48. (Pubitemid 32128711)
70. Picon A, Bertagna X, De Keyzer Y. Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors. Oncogene 1999, 18: 2627-33.
71. Mizoguchi Y, Kajiume T, Miyagawa S, Okada S, Nishi Y, Kobayashi M. Steroid-dependent ACTH-produced thymic carcinoid: regulation of POMC gene expression by cortisol via methylation of its promoter region. Horm Res 2007, 67: 257-62.
72. Ye L, Li X, Kong X, et al. Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. J Endocrinol 2005, 185: 337-43. (Pubitemid 40703873)
73. De Keyzer Y, Bertagna X, Luton JP, Kahn A. Variable modes of proopiomelanocortin gene transcription in human tumors. MoI Endocrinol 1989, 3: 215-23. (Pubitemid 19045693)
74. Lavender PM, Clark AJL, Besser GM, Rees LH. Variable methylation of the 5′-flanking DNA of the human pro-opiomelanocortin gene. J MoI Endocrinol 1991, 6: 53-61.
75. Vallette-Kasic S, Brue T, Pulichino AM, et al. Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 2005, 90: 1323-31.